Summary by Moomoo AI
Arcutis Biotherapeutics, a biopharmaceutical company, has been informed by the United States Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on January 31, 2024, will not undergo review by the commission. The SEC's communication, addressed to Todd Franklin Watanabe, the President and CEO of Arcutis, was dated February 5, 2024. The SEC also reminded the company of its responsibility for the accuracy and adequacy of its disclosures, irrespective of the SEC's review process. The SEC provided contact information for any further questions and copied Ross McAloon on the correspondence.
